Elan looking into dividing firm into two

Irish pharmaceutical company Elan has announced it is to explore the possibility of splitting the company in two.

Any such move would see the €3bn company separating its Athlone-based drug technology business from its bioneurology business, which had a key role in developing multiple sclerosis treatment Tysabri.